UNITED THERAPEUTICS Corp

Income statement revenue $783.3M (-1.9% YoY).Operating income $330.8M (-9.2% YoY).Pre-tax result $372.7M (-8.7% YoY).Net result $333M (+7.6% YoY).

• Adcirca: $6.7M (+3.1% YoY)
• Nebulized Tyvaso: $126M (-18.4% YoY)
• Orenitram: $125.7M (+1.5% YoY)
• Product And Service Other: $6.8M (+23.6% YoY)
• Remodulin: $126.3M (-6.2% YoY)
• Tyvaso DPI: $326.6M (+3.6% YoY)
• Unituxin: $65.2M (+11.6% YoY)
• Operating costs: $353M (+1.9% YoY)
• Other income: $41.9M (-4.6% YoY)
• Income tax expense: $39.7M (-59.9% YoY)